Table 3.
Comparison of other genetic alterations between older and younger AML patientsa
| Variant |
Number of patients with the gene mutation (percentage); Median of RNA expression (delta CT) |
P | ||
|---|---|---|---|---|
| Whole cohort | 60 years or younger, (n=69) | Older than 60 y/o, (n=44) | ||
|
NPM1mut |
38 (33.33%) |
21 (30%) |
17 (38.64%) |
0.227 |
|
FLT3-ITD |
23 (20.18%) |
15 (21/43%) |
8 (18.18%) |
0.433 |
|
FLT3-TKD |
8 (7.02%) |
2 (2.86%) |
6 (13.64%) |
0.036* |
|
NPM1mut/FLT3-ITDneg |
22 (19.30%) |
11(15.71%) |
11 (25%) |
0.164 |
|
CEBPAa |
34 (30.36%) |
18 (26.09%) |
16 (37.20%) |
0.151 |
|
CEBPADouble mutation,b |
9 (78.04%) |
8 (11.59%) |
1 (2.23%) |
0.016* |
|
IDH1c |
3 (3.75 %) |
2 (4%) |
1 (3.3%) |
0.686 |
|
IDH2c |
8 (10 %) |
4 (8%) |
4 (13.2%) |
0.454 |
|
DNMT3Ac |
12 (15 %) |
10 (25.641%) |
2 (4.88%) |
0.095 |
|
MLL |
7 (8.75%) |
4 (8%) |
3 (10%) |
0.528 |
|
Delta BDH2d |
9.006 (4.53-12.36) |
9.051 (4.53-12.36) |
8.915 (6.4-12.15) |
0.102 |
|
ERGd |
10.595 (4.52-19.92) |
10.88 (5.17-19.92) |
9.74 (4.52-19.85) |
0.435 |
|
MN1d |
13.25 (7.75-19.87) |
13.06 (7.76-19.87) |
13.25 (7.75-18.38) |
0.992 |
|
miR-181ad |
3.21 (−3.8-8.44) |
3.3 (−0.03-8.44) |
2.49 (−3.8-8.2) |
0.140 |
| miR-3151d | 12.685 (4.97-15.29) | 12.685 (9.16-15.07) | 12.6 (4.97-15.29) | 0.247 |
Values are number (%) of patients with alteration.
aCEBPAsingle and double mutations.
bCEBPAdouble mutationvs CEBPAsingle mutationvs no mutation.
cOnly 80 patients with high quality of DNA to sequence; 50 patients are 60 y/o or younger patients and 30 patients are high expression.
dMedian delta CT(range).
*Statistically significant (P < 0.05).